To evaluate the association between gene polymorphisms of TNF-a G308A, IL-6 C174G, and coronary atherosclerotic heart disease (CHD) risk.
Introduction
Coronary atherosclerotic heart disease (CHD) characterizes as myocardial ischemia and hypoxia which arises from coronary atherosclerosis. [1] It is a worldwide medical problem and is still one of the leading causes of death in developed and developing countries. [2] At present, the occurrence and development of CHD is generally considered as a chronic inflammatory process characterized by highly specific cytokine response. [3] The regulation network formed by various proinflammatory and anti-inflammatory factors plays an immunomodulatory role in atherosclerosis. [4] Various proteins, cytokines, and adhesion molecules are involved in the development of coronary angiogenesis. [5] Among them, TNF-a and IL-6 have significant effects on the development of coronary heart disease. [6, 7] It has been showed that both of them are capable to damage endothelium function and act on the plaque of the vessel wall, accelerating the rupture of the plaque and triggering the clinical coronary events. [8] As a complex disease, CHD results from the interaction between genetic and environmental factors. [9] Recent studies have suggested that the basic level and biological activity of TNF-a and IL-6 can be influenced by gene polymorphism, which may increase the risk of CHD [10, 11] C863A of TNF-a and C174G of IL-6 are the mostly investigated but the results remain inconsistent. Asifa et al [12] considered that the TNF-a C863A gene polymorphism was associated with the pathogenesis of CHD through case-control study in Pakistan, while Chu et al [13] research in China drew an opposite conclusion. The studies on IL-6 gene polymorphism and risk of CHD are also inconsistent, similar to that research status of TNF-a. [14, 15] This may be due to racial and regional differences, as well as the fact that the sample size is too small to truly reflect the relevance. In order to compare different research results more scientifically and objectively, meta-analysis on this issue coming to be widely carried out also generated conflicting results. Based on it, we carry out a metaanalysis including the genotype data from all eligible investigations in the latest years involving more extensive countries and regions to provide a more precise evaluation of the association between polymorphisms in -308G/A of TNF-a, C174G of IL-6 and CHD susceptibility. the following databases since the establishment of the library to April 2018: the China National Knowledge Infrastructure (CNKI), China Wanfang Database, Chinese biomedical literature database and PubMed, EMBASE, Cochrane library, Web of Science, Sciencedirect. The following search words were combined: "G308A" or "TNF-a" or "C174G"or "IL-6" or "coronary atherosclerotic heart disease." In addition, we searched the references in detail for further research. Furthermore all magazines were retrieved from the first issue, and the relevant conference literature was tracked. If necessary, contact the communication author to obtain information not found by the above retrieval strategies.
Inclusion and exclusion criteria
Studies that meet the following criteria will be adopted: the literature must be a case-control study published both at home and abroad, with good balance and comparability. Languages are limited to Chinese or English. The research should involve gene polymorphisms of TNF-a (G308A), IL-6 (C174G), and CHD. The research should meet the diagnostic criteria of coronary heart disease. Each genotype distribution and individual number in the case and control groups should be listed in the literature, or the corresponding number can be calculated by the frequency of each genotype given.
Studies with the following characteristics will be excluded: not associated with TNF-a (G308A), IL-6 (C174G) polymorphism, and CHD; not a case-control study; the data of genotype frequency and allele frequency in the literature are incomplete or unclear.
Data extraction and quality evaluation
The 2 researchers (Jiang and Zhao) sifted through the title and summary of the studies. Then they read the full text for the secondary screening and eliminated the studies that did not meet the above-mentioned inclusion criteria. For trials that were difficult to determine whether they should be included, consult an expert to discuss the solution. If the information provided in this article was uncertain, contact the original author by phone, email, and other measures to obtain relevant information. We used the 9-star Newcastle-Ottawa scale to evaluate the quality of the studies. It includes 3 aspects: study object selection, group comparability, and exposure factor measurement. In brief, a maximum of 9 points was assigned to each study: 4 for selection, 2 for comparability, and 3 for outcomes. A final score of >6 was regarded as high quality. Then we organized each article included and extracted relevant data: the first author's name, years of publication, country and region, genotype frequencies in the observation group and control group. Hardy-Weinberg equilibrium and quality score of case-control study were showed in Fig. 1 .
Statistical analysis
All the data were analyzed using Stata 12.0 software and the charts related were drawn below. Based on the odds ratio (OR) with a corresponding 95% confidence interval (CI), we counted the pooled odds which were used to analyze the effect on the association. While crossing these studies, Q test and I 2 were used to test the heterogeneity of the included literature firstly. When I 2 >50%, it was proved that there was heterogeneity between the studies, the random effect model was used, and if not, the fixed effect model was used instead. In order to Search for the sources of heterogeneity, we mainly apply subgroup analysis on the national and regional groups. In order to evaluate the stability of the combined results, a sensitivity analysis was conducted for the meta-analysis results after each removal of a case-control study. The Begg funnel plot was used as a criterion for assessing publication bias.
Results

Characteristics of the included studies
Overall, a total of 35 out of 1158 articles were selected for the final meta-analysis. Among the 35 articles, 18 studies [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 1158 studies were correlated with Search words 'G308A'
or'TNF-α' or'C174G'or'IL-6'or'coronary atherosclerotic heart disease' 903 articles were excluded after reading the title and abstract;612 were not case-control studies;The genes studied in 291 papers were not related to this study.
255 articles were read in full 152 were not subject to coronary atherosclerotic heart disease;68 did not examine the number of specific genotypes.
Finally, 35 articles were included.17 studies for TNF-α G308A. 18
literatures about IL-6 C174G and CHD . reported the association between IL-6 (C174G) gene mutation and CHD with 5328 cases and 5077 controls. Seventeen articles [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] demonstrated the relationship between TNF-a (G308A) and CHD with 5360 cases and 6197 controls. The baseline characteristics of the studies related to mutation of IL-6 (C174G) and TNF-a (G308A) were respectively shown in Tables 1 and 2 . All of the 35 articles were published before January 2018. In addition, 29 manuscripts were published in English, and 6 manuscripts were in Chinese.
4.2.
Results of the overall meta-analysis 4.2.1. Meta-analysis of TNF-aG308A polymorphism and CHD risk. Seventeen articles were related to G308A mutation and CHD risk. The results showed that I 2 of all models were >50%, indicating that the included studies had heterogeneity. Subgroup analysis was needed to explore the source of heterogeneity.
Subgroup analysis
Of the 17 articles included, 10 articles were from Asians, 7 articles were from Caucasians. The results were shown in Table 4 . And we conducted subgroup according to different ethnic groups. The I 2 of all models in Asians were <50%, indicating that ethnic differences had an impact on heterogeneity. The results suggested that there was no significantly association between G308A polymorphism and CHD risk under all models from Asians (P > .05) ( Table 3 ).
Meta-analysis of IL-6 C174G polymorphism and CHD risk
Thirteen articles were related to IL-6 C174G polymorphism and CHD emotivity. The results showed that the polymorphism of C174G gene was not significantly associated with CHD risk under heterozygote model (CG vs GG; OR 0.998, 95% CI 0.902-1.103) (P > .05). The results were shown in Table 4 , Fig. 2 . Furthermore, sensitivity analysis revealed that omission of each study made no significant differences on the findings Fig. 3 .
Test for heterogeneity
In the heterogeneity test for the IL-6 C174G genotypes of each model, I 2 of C versus G, CC versus CG+GG, CC versus GG, CC +CG versus GG were >50%, indicating that the included studies had heterogeneity. Subgroup analysis was needed to explore the source of heterogeneity. Table 1 Characteristics of studies on the association between C174G gene polymorphisms of IL-6 and CHD risk.
Total of cases Total of controls
The first author Publicati-on date Country/city/ethnicity GG GC CC G C GG GC CC G C HWE inspec-tion Quality score
Ghazouani et al [16] 2011 Table 2 Characteristics of studies on the association between G308A gene polymorphisms of TNF-a and CHD risk.
The first author Publicati-on date Country/city/ethnicity GG GA AA G A GG GA AA G A HWE inspec-tion Quality score
Işik et al [34] 2016 Table 3 Meta-analysis of TNF-aG308A polymorphism and CHD risk. Table 4 Results of IL-6 C174G polymorphism and CHD risk. 
Subgroup analysis
Of the 18 articles included, 11 studies were from Asians and 7 were from Caucasians. We conducted subgroup analysis on CC versus GG, CC+CG versus GG, CC versus CG+GG, C versus G genotype, and CHD risk according to the ethnicity. The I 2 of (CC vs GG, CC+CG vs GG, CC vs CG+GG, C vs G) in Caucasians were <50%, indicating that ethnic differences had an impact on heterogeneity. And there was no significantly 
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Meta-analysis fixed-effects estimates (linear form) Figure 3 . Sensitivity analyses for IL-6 C174G CG versus GG polymorphism and CHD. CHD = coronary atherosclerotic heart disease, IL-6 = interleukin-6. Table 5 results of IL-6 C174G mutation and CHD risk in subgroup analysis. Table 5 .
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Publication bias
We analyzed the publication bias of articles on the relationship between TNF-a (G308A) and IL-6 (C174G) with CHD risk. The 2 groups of gene funnel plot analysis showed asymmetry 
Discussion
Recently the polymorphisms of TNF-a, IL-6 have aroused great concern among researchers. It has been found that both TNF-a and IL-6 genes have gene polymorphism, which may affect the transcription and expression of genes, and are closely related to the significant increase of CHD risk. [50] TNF-a is an inflammatory cytokine secreted by macrophages and has multiple biological activities. As a starting factor for endothelial dysfunction and endometrial thickening, it can directly damage the vascular endothelial cells and then increase permeability to make more cholesterol deposited in the vascular wall, forming atherosclerotic plaques. [51] Besides it is also capable of promoting the formation of platelet-derived growth factor, breaking blood coagulation-anticoagulant balance, and contributing to thrombosis. [52] Moreover TNF-a reduces lipoprotein activity, participates in insulin resistance, and affects the synthesis of other inflammatory factors. [53] The concentration of TNF-a in plasma can be influenced by gene polymorphism. Among several common mutation sites, the G-308A was the most studied, which is a single nucleotide conversion from guanine (G) to adenine (A) in the TNF-a promoter at position -308. [54] In our conclusions TNFa (G308A) polymorphism was not significantly associated with CHD risk under all models in Asians (P > .05), which is consistent with the results of Wang et al [55] research. To further identify this association, more high quality studies should be merited.
IL-6 is another important cytokine in the proinflammatory response mainly produced by monocytes and macrophages. [56] In the acute stage of inflammation, IL-6 can induce the production of acute inflammatory reactants such as c-reactive protein and fibrinogen, and interact with cytokine network, involved in the pathogenesis of CHD. [57] A study shows that its mRNA levels in atherosclerotic arteries are 40 to 50 times higher than that in nonatherosclerotic vessels. [58] The plasma level of IL-6 are partly adjusted by the IL-6 C174G polymorphism [59] which is located in the upstream promoter region of IL-6 gene. C174G mutation site transforms from a guanine (G) to cytosine (C) at position -174. A 6-year follow-up study in the UK showed that people with genotype of G/C or C/C were more likely to develop CHD when compared with people carrying G/G genotype (OR = 1.54). [60] In our research, there were no connection between IL-6 C174G polymorphism and CHD risk under all models in Caucasians.
Our meta-analysis also has its own drawbacks. For instance the inspections of the funnel plots suggest that they are not symmetrical. This may be due to the fact that sample sizes of many studies included in our meta-analysis were relatively small, and the number of eligible studies included is also not enough. This requires more relevant case-control studies in the future to make the meta-results more objective and scientific.
